AZD-4547featured
WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#:204550
CAS#:1035270-39-3
Description:AZD4547 is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. FGFR inhibitor AZD4547 binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. FGFR, up-regulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cellular proliferation, differentiation and survival.
Price and Availability
AZD-4547, purity > 98%, is in stock. The same day shipping out after order is received.
Chemical Structure
Theoretical Analysis
MedKoo Cat#: 204550Name: AZD-4547CAS#: 1035270-39-3Chemical Formula: C26H33N5O3Exact Mass: 463.25834Molecular Weight: 463.57192Elemental Analysis:C, 67.36; H, 7.18; N, 15.11; O, 10.35
Related CAS #:1035270-39-31394854-62-6
Synonym:AZD4547; AZD-4547; AZD 4547.
IUPAC/Chemical Name:N-(5-(3,5-dimethoxyphenethyl)-1H-pyrazol-3-yl)-4-((3S,5R)-3,5-dimethylpiperazin-1-yl)benzamide
InChi Key:VRQMAABPASPXMW-HDICACEKSA-N
InChi Code:InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+
SMILES Code:O=C(NC1=NNC(CCC2=CC(OC)=CC(OC)=C2)=C1)C3=CC=C(N4C[C@H](C)N[C@H](C)C4)C=C3
Technical Data
Additional Information
Related CAS#Sci-Finder listed CAS#1394854-62-6for AZD-4547ChemIDplus listed CAS#1035270-39-3 for AZD-4547, see website: https://chem.nlm.nih.gov/chemidplus/rn/1035270-39-3 According to Sci-Finder, Chemical name for CAS#1394854-62-6:N-[3-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-5-yl]-4-(3,5-dimethyl-1-piperazinyl)benzamideChemical name for CAS#1035270-39-3:rel-N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]benzamide
References
1: Ramsey MR, Wilson C, Ory B, Rothenberg SM, FaquinW, Mills AA, Ellisen LW. FGFR2 signaling underlies p63 oncogenicfunction in squamous cell carcinoma. J Clin Invest. 2013 Aug1;123(8):3525-38. doi: 10.1172/JCI68899. Epub 2013 Jul 8. PubMed PMID:23867503; PubMed Central PMCID: PMC3726171.
2: Fox EM, Kuba MG, Miller TW, Davies BR, Arteaga CL. AutocrineIGF-I/insulin receptor axis compensates for inhibition of AKT inER-positive breast cancer cells with resistance to estrogen deprivation.Breast Cancer Res. 2013 Jul 11;15(4):R55. [Epub ahead of print] PubMedPMID: 23844554.
3: Katoh M, Nakagama H. FGF Receptors: Cancer Biology and Therapeutics.Med Res Rev. 2013 May 21. doi: 10.1002/med.21288. [Epub ahead of print]PubMed PMID: 23696246.
4: Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA,Cummings CT, Graham DK, Astling D, Tan AC, Heasley LE. A mechanism ofresistance to gefitinib mediated by cellular reprogramming and theacquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2013Mar 25;2:e39. doi: 10.1038/oncsis.2013.4. PubMed PMID: 23552882; PubMedCentral PMCID: PMC3641357.
5: Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K,Zhou M, Gao B, Shen D, Zhang L, Ji J, Gavine PR, Zhang J, Kilgour E,Zhang X, Ji Q. FGFR2 gene amplification in gastric cancer predictssensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res.2013 May 1;19(9):2572-83. doi: 10.1158/1078-0432.CCR-12-3898. Epub 2013Mar 14. PubMed PMID: 23493349.
6: Zhao R, Xie X, Shen GX. Effects of glycated low-density lipoproteinon cell viability, proliferation, and growth factors of mouse embryofibroblasts. Can J Physiol Pharmacol. 2013 Jan;91(1):64-70. doi:10.1139/cjpp-2012-0234. Epub 2013 Jan 21. PubMed PMID: 23369077.
7: Zhang J, Zhang L, Su X, Li M, Xie L, Malchers F, Fan S, Yin X, Xu Y,Liu K, Dong Z, Zhu G, Qian Z, Tang L, Schöttle J, Zhan P, Ji Q, KilgourE, Smith PD, Brooks AN, Thomas RK, Gavine PR. Translating thetherapeutic potential of AZD4547 in FGFR1-amplified non-small cell lungcancer through the use of patient-derived tumor xenograft models. ClinCancer Res. 2012 Dec 15;18(24):6658-67. doi:10.1158/1078-0432.CCR-12-2694. Epub 2012 Oct 18. Erratum in: Clin CancerRes. 2013 Jul 1;19(13):3714. Schöttle, Jakob [added]. PubMed PMID:23082000.
8: Chell V, Balmanno K, Little AS, Wilson M, Andrews S, Blockley L,Hampson M, Gavine PR, Cook SJ. Tumour cell responses to new fibroblastgrowth factor receptor tyrosine kinase inhibitors and identification ofa gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.Oncogene. 2013 Jun 20;32(25):3059-70. doi: 10.1038/onc.2012.319. Epub2012 Aug 6. PubMed PMID: 22869148.
9: Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM,Reichel J, Porrati P, Pellegatta S, Qiu K, Gao Z, Ceccarelli M, RiccardiR, Brat DJ, Guha A, Aldape K, Golfinos JG, Zagzag D, Mikkelsen T,Finocchiaro G, Lasorella A, Rabadan R, Iavarone A. Transforming fusionsof FGFR and TACC genes in human glioblastoma. Science. 2012 Sep7;337(6099):1231-5. doi: 10.1126/science.1220834. Epub 2012 Jul 26.PubMed PMID: 22837387; PubMed Central PMCID: PMC3677224.
10: Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S,Rooney C, Coleman T, Baker D, Mellor MJ, Brooks AN, Klinowska T.AZD4547: an orally bioavailable, potent, and selective inhibitor of thefibroblast growth factor receptor tyrosine kinase family. Cancer Res.2012 Apr 15;72(8):2045-56. doi: 10.1158/0008-5472.CAN-11-3034. Epub 2012Feb 27. PubMed PMID: 22369928.
